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ABSTRACT 
THE ASSOCIATION BETWEEN URINARY BISPHENOL-A, PHTHALATE 
METABOLITES AND BODY FAT COMPOSITION IN US ADULTS USING 
NHANES 
SEPTEMBER 2014 
IRIS CORBASSON, B.SC., UNIVERSITY OF MÜNSTER, GERMANY 
M.S. UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Katherine W. Reeves 
 
Due to the widespread use of the endocrine disruptors Bisphenol-A (BPA) and 
phthalates in many plastic consumer goods, medical equipment, and personal care 
products, more than 95% of the US population show detectable levels of urinary BPA 
and phthalate metabolites. Both have been linked to increased body mass index (BMI in 
kg/m2), an inexpensive diagnostic tool for obesity, which may however not reflect body 
fatness. Since excess body fat is associated with cardiovascular diseases, cancer and type 
II diabetes, it is important to understand the relationship between body fat composition 
and exposure to BPA and phthalates, a relationship that is still unknown. Using 
NHANES 1999-2006 data on adults aged >20 years, we investigated the relationship 
between urinary BPA (N=2,534), monoethyl-phthalate (mEP, N=5,431), monobutyl-
phthalate (mBP), monoethylhexyl-phthalate (mEHP) and monobenzyl-phthalate (mBzP, 
each N=5,436) measured by high-performance liquid chromatography tandem mass 
spectrometry, and body fat composition measured as lean mass (LM, grams), fat mass 
(FM, grams) and percent body fat (%BF) using Dual Energy X-ray Absorptiometry. A 
multivariable linear regression analysis yielded that independently of BMI, BPA, mBP, 
and mBzP were inversely associated with LM (quartile 4 b=-862.16 (354.65), -731.76 
 vii 
(248.89), -909.13 (252.32), respectively; all p<0.02, p-trend<0.02); mEHP and FM were 
inversely associated (quartile 4 b=-297.98 (144.87), p=0.04, p-trend<0.02); BPA, mBP, 
and mBzP were positively associated with %BF but not clinically significant. These 
results provide novel insights in the relationship between urinary BPA, phthalates and 
LM independent of BMI, and it highlights the need for prospective studies establishing 
temporality of this relationship. 
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CHAPTER 1 
INTRODUCTION 
Endocrine disrupters such as Bisphenol-A (BPA) and phthalates are pervasive in 
our environment and we are almost constantly exposed to them through dermal exposure, 
diet and inhalation of household dust.1,2 BPA is used in many plastic consumer products, 
dental sealants, thermal receipts, and Polyvinyl chloride (PVC).1 Phthalates are used in 
numerous household hardware products, plastic medical equipment, medications and 
personal care products.2-5 Once phthalates enter the human body, they are rapidly 
metabolized into monoesters, which are known to act as endocrine disruptors.6  
According to the National Health and Nutrition Examination Survey (NHANES), 
urinary BPA is detectable in 95% of the US adult population and several kinds of urinary 
phthalate metabolites are detectable in 97% of the total US population.3,4,7 It is important 
to understand how exposure to these compounds is related to excess body fat , because 
BPA and phthalate metabolites are known endocrine disrupters that interfere with energy 
use and metabolism regulation, which might lead to weight gain. Given that obesity is a 
serious public health problem in the US, as 78 million adults were obese in 2009-2010,8 it 
is crucial to identify potentially modifiable obesity risk factors,  such as exposure to 
endocrine disruptors BPA and phthalates. 
The biological mechanism underlying the positive relationship between urinary 
BPA and obesity could be explained by its estrogen-like effect that is known to induce 
insulin resistance and weight gain.7,9 Also, obese individuals might have a higher energy 
diet than non-obese individuals, implying that a higher BPA concentration is due to a 
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higher intake of BPA contaminated packaged foods.10 Moreover, as BPA is known to be 
lipophilic, higher body fat may imply higher BPA concentration storage in adipose tissue 
which might lead to higher urinary BPA levels.9 However, this mechanism remains 
controversial, as studies were unable to find a significant correlation between Body Mass 
Index (BMI in kg/m2) and BPA concentration in adipose tissue11.  
There is evidence that the biological mechanism underlying the effect of 
phthalates on obesity may differ by the type of phthalates.2 Ingested phthalates diethyl-
phthalate (DEP), di-n-butyl-phthalate (DBP), benzylbutyl-phthalate (BBzP), and di-2-
ethylhexyl-phthalate (DEHP) rapidly metabolize into the monoesters mEP, mBP, mBzP, 
and mEHP respectively, which are known to interfere with the regular endocrine 
functions.6 The metabolite mEHP has been found to strongly affect biological pathways 
that regulate fatty acid storage and glucose metabolism; mBzP strongly affects the 
thyroid function, which controls energy use and hormone balance; and all four 
metabolites have been found to have antiandrogenic effects. 2  
Overall, most previously conducted epidemiological studies investigating the 
relationship between either urinary BPA or urinary phthalate metabolites and body 
fatness are limited to BMI and waist circumference (WC) as obesity measures, but they 
do not accurately reflect body fatness or body fat composition.12,13 A better body fatness 
measurement is the use of dual-energy X-ray absorptiometry (DXA) scans that estimate 
fat mass (FM), lean mass (LM) and percent body fat (%BF). 12 Since excess body fat has 
been shown to be linked to a number of adverse health outcomes,8,13 it is important to 
assess the relationship between body fatness and possible modifiable risk factors such as 
exposure to BPA and phthalates. Previous cross-sectional studies have shown that that 
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urinary BPA, mEP, mBP, and mBzP, are positively related to obesity when measured by 
BMI and WC, 2,9,10,14,16 but it remains unclear how those compounds are related to FM, 
lean mass LM or percent body fat %BF. Some investigators found a positive yet weak 
relationship between BPA and body fat composition measures using DXA, but the study 
samples used were limited to pre-menopausal non-obese women of the elderly.5, 15 
Therefore, the relationship between urinary BPA or phthalate metabolites and DXA 
measures in the general US population remains unknown.15 
NHANES data includes Dual Energy X-ray Absorptiometry (DXA) measures for 
subjects describing the individual’s body fat distribution in FM, LM and %BF. To our 
knowledge, the relationship between either urinary BPA or urinary phthalate metabolites 
and DXA measures has not been studied in a large population-based sample. Therefore, 
we evaluated the association between urinary BPA, urinary phthalate metabolites and 
body fat measures, assessed by DXA scans, among adults using NHANES data. We 
hypothesized that there is a positive association between urinary BPA quartiles and FM 
and %BF, and a negative association between BPA and LM. We further hypothesized 
that there is a positive relationship between each urinary phthalate metabolite measured 
in quartiles and FM, and %BF, and a negative association with LM.  
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CHAPTER 2 
METHODS 
Study Design 
This analysis employs a cross-sectional study design using data from the National 
Health and Nutrition Examination Survey (NHANES). NHANES is designed to produce 
health statistics for the US population by assessing the health and nutritional status of 
non-institutionalized adults and children in the United States. More specifically, nearly 
7000 residents are randomly selected each year and invited to participate. The NHANES 
interview includes demographic, socioeconomic, dietary, and health-related questions. 
Examinations comprise medical, physiological measurements and laboratory tests of 
specimens. The National Center for Health Statistic’s Institutional Review Board (IRB) 
has reviewed and approved the NHANES protocol.16 
To examine the association between urinary phthalate metabolites and DXA 
measures (LM, FM, %BF), we combined data from four NHANES survey cycles (1999-
2000, 2001-2002, 2003-2004, 2005-2006) as those are the years when DXA body fat 
composition measures were performed. In addition, to examine the association between 
urinary BPA and DXA measures, we used NHANES data from 2003-2004 and 2005-
2006, as urinary BPA measures were only taken during these two survey cycle during 
which DXA measures are also available.  
Study population 
Because there are substantial differences in the biology of environmental 
exposures and body fat composition between children and adults, we restricted our 
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analysis to adults aged 20 or older for the purpose of the proposed analysis. BPA and 
phthalate measurements were performed on a randomly selected one third subsample in 
the respective NHANES survey cycle. We only included participants for whom BPA 
and/or phthalate measurements as well as DXA measures are available.  
For the BPA analysis, we had 2,534 eligible participants and excluded 84 (3.19%) 
with missing BPA levels and 32 (1.21%) with highly variable imputed DXA measures. 
Out of the remaining 2,534 (96.20%), about 28% had imputed DXA measures (see 
Appendix Table 13).  
We had 5,688 eligible participants for all phthalate metabolite analyses and 
excluded 202 (3.55%) with missing mEP measures and 197 (3.46%) with missing mEHP, 
mBP, and mBzP measures. We further excluded 103 (1.81%) with highly variable DXA 
measures. Out of the total 5,431 (95.48%) participants for the mEP analysis and the 5,436 
(95.57%) participants for the mEHP, mBP and mBzP analyses, about 23% had imputed 
DXA measures (see Appendix Table 13). 
Exposure Assessment 
Urinary BPA concentrations: 
Total urinary BPA concentration was measured in spot urine samples using online 
solid-phase extraction coupled to isotope dilution high performance liquid 
chromatography-tandem mass spectrometry (SPE-HPLC-MS/MS).17,18 The precision of 
this method was evaluated by repeated measures in two quality control pools over time. 
Depending on the concentration, the coefficient of variations (CV) ranged from 12.1% - 
18.6% in 2003-2004, and from 11.2%-12.6% in 2005-2006.17,18 Urinary creatinine also 
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was measured in each urine sample and was used in this analysis in order to adjust for 
urinary dilution. 
Urinary phthalate concentration: 
We focused on the four most prevalent phthalate metabolites: monobutyl 
phthalate (mBP), monoethylhexyl phthalate (mEHP), monoethyl phthalate (mEP), and 
monobenzyl phthalate (mBzP).3 For the NHANES 1999-2000 and 2001-2002 survey 
cycles, the urine samples were analyzed using high-pressure liquid chromatography 
tandem mass spectrometry (HPLC-MS/MS).19,20 The precision of this method was 
evaluated by repeated measures of quality control pools over time. Depending on 
concentration and measurement period, the CV in NHANES 1999-2000 range from 7.2 - 
22.1% (mBP), 10.5 – 18.2% (mEHP), 4.9 – 10.0% (mEP), and 9.6 – 13.8% (mBzP).19 
The CV in NHANES 2001-2002 range from 4.0 – 17.2% (mBP), 8.6 – 15.8% (mEHP), 
4.6 -10.6% (mEP), 5.4 – 14.2% (mBzP).20  
For the NHANES 2003-2004 and 2005-2006 survey cycles, the urine samples 
were analyzed using high performance liquid chromatography-electrospray ionization-
tandem mass spectrometry (HPLC-ESI-MS/MS).21,22 The CV range from 7 – 7.4% 
(mBP), 7.6 – 10.5% (mEHP), 5.1 – 6% (mEP), 6.3 – 6.4% (mBzP) in 2003-2004,21 and 
from 7.5 – 17.4% (mBP), 6.3 – 12.0% (mEHP), 2.9 - 5.2% (mEP), 6.8 – 8.9% (mBzP) in 
2005-2006.22 Urinary creatinine also was measured in each urine sample and was used in 
this analysis in order to adjust for urinary dilution. 
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Outcome Assessment 
Our outcomes of interests are lean mass (LM in gm), fat mass (FM in gm), and 
percent body fat (%BF) as assessed by Dual Energy X-ray Absorptiometry (DXA). From 
1999 to 2004, DXA was administered to eligible participants aged 8 years or older. In 
2005-2006, DXA was administered to eligible participants between the ages 8 to 59.23 
Exclusion criteria for DXA examination were: pregnancy, self-reported history of 
radiographic contrast material use in the past 7 days, self-reported nuclear medicine 
studies in the past 3 years, and self-reported weight over 300 pounds or a standing height 
over 6’5’’ (limitation for examination table). The NHANES DXA data in all four survey 
cycles were collected with a Hologic QDR-4500A fan-beam densitometer (Hologic, Inc. 
Bedford Massachusetts). Up until mid-2005, Hologic software version 8.26:a3 was used 
to administer all scans; in 2005 the software was updated to Hologic Discovery v12.4. 23 
The health technicians performing DXA measures are trained to follow detailed protocols 
on maintenance and calibration of the DXA equipment with specific quality control 
checks performed daily and weekly.24 
Because DXA measures were missing for about 21% of the population eligible for 
DXA scans, and missingness was related to age, BMI, height and weight, NHANES used 
multiple imputation techniques to create predicted DXA measures in order to avoid bias 
due to missingness not at random (MNAR).25 We used these multiply imputed DXA 
measures for our analysis, but we excluded those subject with highly variable imputed 
DXA measures.23  
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Covariate Assessment  
Information on demographics, socioeconomic status, dietary habits and health-
related issues was collected through NHANES interviews. Furthermore, medical, 
physiological and laboratory tests were conducted during NHANES examinations. Based 
on covariates selected by previous studies investigating the relationship between urinary 
BPA or urinary phthalate metabolites and obesity, we considered age, gender, 
race/ethnicity, marital status, income, education, physical activity, smoking, alcohol 
consumption, total calorie intake, total fat intake, total serum cholesterol, diabetes, 
hypertension, BMI, standing height, weight, and WC.2,5,9,10,14,26,27 
Data Analysis 
In order to account for urinary dilution, we standardized BPA and phthalate 
metabolite levels by urinary creatinine. We cross-tabulated LM, FM, %BF and covariates 
by creatinine standardized urinary BPA and phthalate metabolite quartiles. Analysis of 
variance and chi-square tests were used for continuous and categorical variables 
respectively to assess potential confounders. In case of heteroscedasticity or small cell 
counts, Kruskal-Wallis and Fisher’s exact test were used instead. We modeled the 
association between the raw urinary BPA levels, raw urinary phthalate metabolites 
(continuous and quartiles) and LM, FM and %BF separately using linear regression with 
adjustment for urinary creatinine as an independent variable in order to adjust for urinary 
dilution. Because urinary creatinine is known to be associated with age, gender and 
race/ethnicity,28 we included these covariates in all of our multivariable analyses. We 
created three separate multivariable models: First with adjustment for creatinine, age, 
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gender, and race/ethnicity (model 1); second with additional adjustment for BMI (model 
2), and third we applied the Hosmer-Lemeshow model building process (model 3). For 
the third model, covariates were evaluated with each of the three outcomes separately in 
order to assess potential confounders. Further, all covariates with p-values of at least 0.25 
were included in the full model and their individual effect on the full model was 
evaluated using partial F-test. For borderline significant effects, the variable was kept in 
the model, if other regression coefficient were changed by more than 15%. In addition, 
we reported each final model stratified by BMI category using the cut-off points for 
normal weight (BMI= 18.5-24.99 kg/m2), overweight (BMI= 25-29.99 kg/m2), and obese 
(BMI>= 30 kg/m2) as defined by the World Health Organization.29 Due to a small 
number of people, we grouped those subjects with a BMI<18.5 kg/m^2 together with the 
normal weight subjects. In order to check for correlation between BMI and the outcome 
measures LM, FM, and %BF, we performed a correlation analysis using Pearson’s 
correlations coefficients in both the total population and in the subpopulation consisting 
of subjects with only non-imputed DXA measures. The latter was performed because of 
the concern that BMI might be highly related to the imputed DXA measures due to the 
use of BMI in the multiple imputation models.  
For all of our statistical analyses, we used STATA Statistical Software 
(StataCorp. 2013, Release 13. College Station, TX: StataCorp LP). 
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CHAPTER 3 
RESULTS 
In both the BPA and the phthalate metabolite analyses, our study population 
consisted of nearly 51% men and 49% women. The race/ethnicity distribution was 
similar in both samples; 49.5%-50.5% were non-Hispanic white, 20.9%-22.0% were non-
Hispanic black, 19.4%-21.7% were Mexican American, 3.7%-4.4% were other Hispanic, 
and 3.5%-4.4% were other/multiethnic. The mean age was 47.7 (sd=17.5) years and 48.9 
(sd=18.5) years in the BPA and the phthalate metabolite analysis, respectively. 
Within the respective study samples, the total population geometric means were 
2.04 μg/g creatinine (95%CI=1.97-2.12) for BPA, 131.87 μg/g creatinine 
(95%CI=127.12-136.80) for mEP, 2.89 μg/g creatinine (95%CI=2.80-2.98) for mEHP, 
18.35 μg/g creatinine (95%CI=17.92-18.79) for mBP, and 7.74 μg/g creatinine 
(95%CI=7.53-7.95) for mBzP. 
A cross-tabulation of each covariate by creatinine standardized BPA quartile 
yielded that LM, and %BF, as well as gender, age, height, weight, and WC, differed 
significantly between the BPA comparison groups, while FM, race/ethnicity, and BMI 
appeared to be similar across all groups (Table 1). Within the crude creatinine 
standardized mEP analysis, LM, FM, %BF, as well as gender, age, race/ethnicity, BMI, 
height, weight, and WC differed significantly between the four comparison groups (Table 
2). The outcome measures LM, and FM, as well as age, BMI, height, weight, and WC 
differed significantly between the mEHP comparison groups, while %BF, gender, and 
race/ethnicity appeared to be similar (Table 3). The outcome measures LM, and %BF, as 
well as age, race/ethnicity, BMI, height, weight, and WC, differed significantly between 
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the mBP comparison groups, while FM and gender appeared to be similar across all 
groups (Table 4). All three outcome measures LM, FM, %BF, as well as age, gender, 
height differed significantly between the mBzP comparison groups, while weight, BMI, 
and WC appeared to be similar (Table 5). A Pearson correlation analysis yielded that 
BMI and FM are highly correlated (coefficient=0.92) in the total population of both the 
BPA and phthalate analyses; BMI and LM as well as %BF were moderately correlated 
(coefficient= 0.51-0.59). In the sub-population of subjects with only non-imputed DXA 
measures, the Pearson correlation analysis between BMI and the outcome measures 
yielded a coefficient of 0.88 for FM, 0.43-0.44 for LM, and 0.54-0.56 for %BF. 
The multivariable linear regression analysis using BPA as a continuous variable 
only showed a significant negative association with LM in model 2 (b=-21.51 (10.31), 
p=0.037) (Table 6). All other associations between urinary BPA and FM, as well as %BF 
were non-significant. Moreover, there was no significant association between any 
phthalate metabolite for each of the three outcomes LM, FM, and %BF when the 
phthalate metabolites were analyzed as a continuous variable (Table 6-8).  
The following analyses model the exposure measures as categorical variables 
using quartiles (Q1-Q4) with the first quartile (Q1) used as the reference group:  
Results of the Lean Mass analysis: 
Using linear regression with adjustment for creatinine, age, gender, and 
race/ethnicity, we only observed a significant 1,154.85 (524.14) gm mean increase of LM 
for Q2. However, when the model was further adjusted for BMI, we observed a 
significant 1,263.23 gm (356.77) decrease in mean LM for Q4, with a p-trend of <0.001. 
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Our final model adjusted for creatinine, age, gender, race/ethnicity, BMI, family income, 
vigorous physical activity, moderate physical activity, WC, total calorie intake, serum 
cholesterol. It showed 862 gm (354.65) mean LM decrease for Q4, with a p-trend=0.017 
(Table 6). 
Within the mEP analysis, the linear regression with adjustment for age, gender 
and race/ethnicity yielded a significant increase in LM of 887.91 gm (363.87) for Q4. 
When additionally adjusting for BMI, there was a borderline significant decrease in LM 
of 414.95 gm (222.68) for Q4 (p=0.062), with a p-trend= 0.022. There was not significant 
association between any of the mEP quartiles and LM in the full model, but it showed a 
significant trend of lower LM with increasing mEP (p-trend=0.035) (Table 6).  
Within the mBP analysis, the model adjusted for age, gender and race/ethnicity 
showed a mean decrease of 1,319.47 gm (404.05) in LM for Q4. When further adjusting 
for BMI, we observed a decrease of 881.64 gm (246.48) in LM between Q4 and Q1. We 
observed a highly significant decrease of 731.76 gm (246.48) in LM for Q4 in the full 
model (Table 6).  
Within the mEHP analysis, we did not observe a significant association between 
mEHP and LM in any of the three models (Table 6). 
Within the mBzP analysis, there was no significant association with LM when 
adjusting for age, gender and race/ethnicity. There was a significant 592.98 gm (22.6.46) 
decrease for Q3 and a 1,070.43 gm (248.06) decrease for Q4 (p-trend<0.001) when the 
model was further adjusted for BMI. The full model showed a 707.35 gm (223.25) 
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decrease in LM for Q3, and a 909.13 gm (252.32) decrease in LM for Q4 (p-trend<0.001) 
(Table 6).  
Results of the Fat Mass analysis: 
When adjusting for age, gender and race/ethnicity, we observed a significant 
mean increase in FM for each BPA quartile with a mean 2,106 gm (736.83) in Q4 (p-
trend= 0.009). When further adjusting for BMI, we only observed non-significant 
increases in mean FM for each BPA quartile. The full model adjusted for creatinine, age, 
gender, race/ethnicity, BMI, education, diabetes, WC, total calorie intake and total fat 
intake and only showed non-significant increases in FM for each BPA quartile (Table 7). 
When adjusting the mEP model for age, gender, race/ethnicity, we observed a 
mean increase in FM of 1,995.70 gm (474.43) (p<0.001). When we further adjusted for 
BMI as well as additionally for education, marital status, vigorous physical activity, 
diabetes, WC, alcohol intake, total calorie intake and total fat intake, there was no 
significant association between mEP quartile and FM (Table 7).  
There was no significant association between mBP and FM in any of the models 
(Table 10b).  
There was no significant association between mEHP and FM in the model 
adjusted for age, gender and race/ethnicity. When we further adjusted for BMI, we 
observed a significant decrease in FM of 394.87 gm (155.61) for Q4. The full model was 
additionally adjusted for education, vigorous physical activity, diabetes, WC, alcohol 
intake, total calorie intake and total fat intake and showed a significant decrease in FM of 
 14 
319.91 gm (140.90) for Q3 and a decrease in FM of 297.98 gm (144.87) for Q4 (p-
trend=0.016) (Table 7). 
Within the mBzP analysis, the model adjusted for age, gender, and race/ethnicity 
showed a mean increase in FM of 1,771.72 gm (529.45) for Q4. The models that further 
adjusted for BMI as well as the fully adjusted model did not show a significant 
association between mBzP and FM (Table 7). 
Results of the % Body Fat analysis: 
There was a highly significant mean increase of 1.26% (0.37) -1.44% (0.40) in 
%BF for each BPA quartile compared to the lowest (p-trend=<0.001), when adjusted for 
age, gender, and race/ethnicity. After further adjusting for BMI, we observed a low 
statistically significant mean increase of 0.50% (0.24) in %BF for Q3 and an increase of 
0.67% (se=0.26) in %BF for Q4. The fully adjusted model showed a similar increase in 
%BF as the previous model, but with only a statistically significant increase in %BF for 
Q4 (Table 8). 
There was a significant increase in %BF in each of the mEP quartiles with the 
highest increase in %BF of 1.16% (0.26) for Q4 (p-trend <0.001), when adjusting for age, 
gender, and race/ethnicity. When further adjusting for BMI, only the increase of 0.41 
%BF for Q3 remained significant. Similarly, the full model only showed a significant 
increase of 0.49% (0.16) in %BF for Q3, but it showed a significant trend of higher %BF 
with increasing mEP (p-trend=0.022) (Table 8). 
We did not observe a significant association between mBP and %BF when 
adjusted for age, gender, race/ethnicity. When further adjusting for BMI, there was a 
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significant increase in BF of 0.35% (0.17) comparing the third to the lowest mBP 
quartile. Similarly, the full model adjusted for marital status, vigorous physical activity, 
smoking status, diabetes, WC, alcohol intake, total calorie intake and serum cholesterol 
and only showed a significant increase of 0.43% (0.17) in BF when comparing the third 
to the lowest mBP quartile (Table 8). 
There was no significant association between mEHP and %BF in any of the 
models.  
Within the mBzP analysis, we observed a significant increase or 1.20% (0.29) in 
BF for Q4 when adjusting for age, gender, race/ethnicity (p-trend<0.001). When further 
adjusting for BMI, the increase in %BF diminished to 0.43% (0.18) but remained 
significant (p-trend=0.013). The full model showed a significant increase of %BF of 
0.61% (0.18) (p-trend<0.001) (Table 8). 
Overall, after repeating the analyses of model 1 for each association between our 
exposures and outcomes within the sub-population of subjects with only non-imputed 
DXA measures, the results for LM were similar to those of the total population; the 
results for FM were closer to the null; and the results for %BF were slightly attenuated 
for mEP and mBzP, but similar to the total population results for BPA, mBP, and mEHP 
(Table 12). 
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CHAPTER 4 
DISCUSSION 
We found a significant inverse association between urinary BPA, mBP, mBzP 
and LM, independent of BMI. Surprisingly there was a negative association between 
mEHP and FM after adjustment for BMI. Moreover, all statistically significant 
associations in the %BF analysis were very small and did not seem to be clinically 
meaningful.  
With regard to previous studies, only limited data are available on the relationship 
between urinary BPA and body fat composition measures. One cross-sectional study 
using DXA measures found a positive yet weak relationship between urinary BPA and 
FM after adjusting for age and BMI (partial correlation coefficient=0.193), but they did 
not find an association between BPA and fat free mass.15 Our findings differ from these, 
but the study population only consisted of pre-menopausal non-obese women, which 
makes it difficult to put our findings in perspective.15  
We only observed a positive relationship between BPA and FM before adjustment 
for BMI, but not independent of BMI. This might be explained by the high correlation 
between BMI and FM, which results in an attenuation of the effect of BPA on FM after 
adjustment for BMI. Therefore, BMI and FM may essentially capture the same fatness 
measure and both seem to be individually related to high urinary BPA.  These findings 
are in line with previous literature, as other cross-sectional studies with samples similar to 
ours have found a 28% to 76% increased risk of obesity measured by BMI for the highest 
BPA quartile.9,10,14  
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The literature assessing the association between phthalate metabolites and body 
fat composition measures is limited, as most studies focus on fat measures and to our 
knowledge none have investigated the relationship between phthalates metabolites and 
LM. A positive and statistically significant association was found between urinary mBzP, 
mEP and abdominal obesity measures by WC with a male cohort, but results were not 
adjusted for BMI.27 A strong positive association was found between urinary mBzP 
quartiles and BMI in men aged 20-59.2 Conversely, a negative association has been found 
between urinary mEHP quartiles and BMI in women of the same age group.2  A slight 
borderline significant negative association was found between serum mEHP and waist-
hip ratio in men and a slight borderline significant positive association was found 
between monoisobutyl-phthalate (a structural isomer of monobutyl-phthalate (mBP)30) 
and BMI in women. 5  However this study was restricted to the elderly aged 70 and 
exposure was measured in blood instead of urine samples, which makes it difficult to 
compare their results to ours. Yet, overall these results are consistent with ours, as we 
found an association between mEP, mBzP and FM before BMI adjustment but not 
afterwards, which could imply that our initial results were confounded by BMI, but there 
is no association between mEP, mBzP and FM independent of BMI. With regard to 
mEHP, there seems to be a negative association between this phthalate metabolite and 
FM, which was also observed in previous literature that used different obesity measures. 
However, it has been found that the metabolite mEHP is not a good surrogate for the 
parent phthalate DEHP, because mEHP only accounts for a small proportion of its 
metabolites and the analysis of other metabolites such as mEOHP and mEHHP are a 
more appropriate measure of exposure to DEHP.31 Therefore, we believe that our 
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observed negative association between mEHP and FM could due to its poor 
representation of the full exposure to DEHP. 
Our study has several limitations. We are unable to make inferences about a 
causal relationship between exposure to BPA and phthalates and LM due to the cross-
sectional study design and the inability to assess temporality. In addition, confounding 
can occur by unmeasured confounders such as medication use. We are unable to measure 
the use of medications that include phthalates, which could contribute to certain urinary 
phthalate metabolite levels,3 but might also be associated with high FM, if the medication 
is taken for obesity related health issues. However, since we did not find a positive 
association between BPA, phthalates and FM independent, we are confident that our 
results are not subject to confounding by medication. 
In addition, BPA and phthalate metabolites were only measured in one single spot 
urine sample, which may not accurately represent an individual’s typical exposure as 
studies have shown that urinary BPA levels vary considerably over longer periods of 
time.32 This type of misclassification is non-differential and we believe the impact of this 
is modest, possibly biasing the observed results towards the null. Moreover, studies have 
shown that urinary phthalate metabolite levels are relatively stable over time, probably 
because phthalates are ubiquitous in our environment, suggesting a rather continuous 
exposure. 33 Therefore, a single spot urine measurement may still be a close 
representation of typical exposure. This type of misclassification is non-differential and 
we believe the impact of this to be modest, biasing the observed results towards the null. 
We restricted our analysis to non-pregnant adults without amputations, and used 
multiply imputed data for those who were unable to undergo a DXA scan due to e.g. high 
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body weight or the presence of pacemakers in their body. This allows us to generalize to 
men and women with high risk of obesity related health issues. However, we excluded 
those whose imputed DXA measure were highly variable, which occurred mostly among 
those with missing data on weight and WC.23  The physiological mechanism linking 
urinary BPA and phthalate metabolites to body fat composition is likely the same among 
those excluded and included in the analysis. However, because body fat composition is 
highly variable among pregnant women, and the impact of BPA and phthalate on body 
composition may differ greatly due to hormonal differences, we should not generalize our 
findings to pregnant women. 
Our secondary analysis of model 1 in the sub-population of subject with only non-
imputed DXA measures showed attenuated effects of BPA, and phthalate metabolites on 
FM, but not on LM. We expected a bias towards the null within the secondary analysis 
after omitting subjects with multiple imputed DXA measures, because they were less 
likely to be eligible for a DXA scan examination due to an obesity related health concern 
(e.g. having a pace maker or body weight >300 pounds).  These findings suggest that the 
use of multiply imputed DXA measures in analyses examining the association between 
BPA, phthalates and FM may be useful to avoid bias and to detect significant differences 
in FM between the comparison groups without adjustment for BMI.  
Conclusion 
Our results add to the current literature as we are the first to assess the 
relationship between urinary BPA, phthalate metabolites and DXA measures on a large 
population scale. Most previous studies assessed the relationship between BPA, phthalate 
metabolites and obesity using BMI and WC on the large population scale, but DXA 
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measures were only used in specific sub-populations. Our findings suggest that BPA, 
mBP, mBzP are inversely associated with LM independent of BMI, but not with FM. 
However, previous literature assessing the relationship between BPA, phthalates and LM 
is very limited and more studies should be conducted to analyze this relationship further. 
On the other hand, the positive relationship between BPA, phthalate metabolites and 
obesity can be explained by BMI, as we only found null results for FM independent of 
BMI. These findings suggest that BMI may indeed be an adequate fatness measure in 
order to assess the relationship between these endocrine disrupters and obesity. The 
relationship between mEHP and body fat composition measures remains unclear and a 
different metabolite of DEHP should be used as a surrogate of exposure to this parent 
phthalates in future studies. Prospective studies are needed in order to assess the timing 
between BPA or phthalates exposure and weight gain. Further research in this area is 
important because of the high obesity prevalence in the United States and the ubiquity of 
BPA and phthalates in our environment.  
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Table 1: Means and standard deviations of Lean Mass, Fat Mass, % Body Fat and covariates 
according to creatinine standardized urinary BPA quartiles 
 
Q1 (n=634) Q2 (n=650) Q3 (n=616) Q4 (n=633) p-value
urinary BPA,  μg/g creatinine <1.15 1.15-2.00 2.01-3.37 >3.37
Lean mass, gm (sd) 52,891.20 (12,865.85) 51,716.01 (13,299.28) 49,807.63 (12,878.70) 49,718.33 (12,268.21) <0.001
Fat mass, gm (sd) 27,504.30 (11,520.88) 28,617.54 (12,361.01) 27,763.37 (11,495.05) 29,084.37 (12,101.98) <0.0639
Body fat, % (sd) 32.61 (8.83) 33.95 (8.92) 34.22 (8.52) 35.14 (8.64) <0.001
Gender, n(%)
Male
Female
385 (60.73)
249 (39.27)
342 (52.62)
308 (47.38)
281 (52.62)
335 (47.38)
292 (45.62)
341 (54.38)
<0.0001
Age, years, m(sd) 48.72 (16.31) 47.58 (17.70) 45.67 (17.44) 48.62 (18.39) <0.0029
BMI, kg/m2, m(sd) 28.45 (6.33) 28.77 (6.55) 28.12 (6.35) 28.75 (6.52) 0.2426
Height, cm, m(sd) 169.82 (10.24) 168.61 (10.34) 167.59 (9.97) 166.94 (9.71) <0.0001
Weight, kg, m(sd) 82.15 (20.10) 82.14 (21.50) 79.28 (20.34) 80.46 (20.39) 0.0348
Waist circumference, cm, m(sd) 98.00 (15.54) 98.35 (16.20) 96.09 (15.17) 98.21 (15.54) 0.0403
Race/ethnicity, n(%)
Mexican American
Other Hispanic
Non-Hispanic White
Non-Hispanic Black
Other/Multi-ethnic
140 (22.08)
16 (2.52)
290 (45.74)
155 (24.45)
33 (5.21)
136 (20.92)
27 (4.15)
331 (50.92)
130 (20.00)
26 (4.00)
106 (17.21)
24 (3.90)
322 (52.27)
138 (22.40)
26 (4.22)
109 (17.22)
26 (4.11)
336 (53.08)
135 (21.33)
27 (4.27)
0.125
Income, n(%)
$0 - $9,999 
$10,000 - $19,999
$20,000 - $34,999  
$35,000 - $54,999
$55,000 - $74,999
$75,000 + 
47 (7.87)
88 (14.74)
124 (20.77)
118 (19.77)
65 (10.89)
155 (25.96)
49 (7.90)
108 (17.42)
141 (22.74)
115 (18.55)
79 (12.74)
128 (20.65)
55 (9.29)
105 (17.74)
125 (21.11)
129 (21.79)
67 (11.32)
111 (18.75)
68 (11.30)
132 (21.93)
131 (21.76)
109 (18.11)
60 (9.97)
102 (16.94)
0.005
Education, n(%)
Below High School
High School Diploma
Above High School 
180 (28.39)
149 (23.50)
305 (48.11)
180 (27.73)
144 (22.19)
325 (50.08)
152 (24.76)
150 (24.43)
312 (50.81)
158 (25.00)
171 (27.06)
303 (47.94)
0.36
Marital status, n(%)
Married
Widowed
Divorced
Separated
Never married
Living with partner
386 (60.92)
38 (6.01)
51 (8.07)
11 (1.74)
110 (17.41)
37 (5.85)
354 (54.55)
45 (6.93) 
53 (8.17)
24 (3.70)
120 (18.49)
53 (8.17)
347 (56.33)
37 (6.01)
61 (9.90)
22 (3.57)
103 (16.72)
46 (7.47)
310 (48.97)
59 (9.32)
75 (11.85)
17 (2.69)
125 (19.75)
47 (7.42)
0.009
Moderate physical activity, n(%) 350 (55.21) 367 (56.46) 331 (53.73) 327 (51.66) 0.349
Vigorous physical activity, n(%) 225 (35.49) 217 (33.38) 199 (32.31) 169 (26.70) 0.006
Smoking status, n(%)
Never
Past
Current
335 (52.92)
162 (25.59)
136 (21.48)
338 (52.08)
149 (22.96)
162 (24.96)
307 (49.92)
141 (22.93)
167 (27.15)
303 (47.94)
158 (25.00)
171 (27.06)
0.193
Diabetes, n(%)
Yes
Borderline
47 (7.42)
10 (1.58)
58 (8.94)
6 (0.92)
49 (7.95)
5 (0.81)
87 (13.74)
11 (1.74)
0.002
Hypertension, n(%) 227 (38.47) 213 (34.86) 178 (31.17) 235 (40.17) 0.007
Alcohol consumption 
(#drinks/month in past year), 
( d)
3.95 (7.10) 4.13 (7.12) 4.43 (7.36) 4.23 (7.39) 0.7116
Total calorie intake, kcal, m(sd) 2,216.43 (978.69) 2,241.17 (1062.55) 2,184.06 (1,057.16) 2,135.45 (994.08) 0.3022
Total fat intake, gm, m(sd) 83.24 (45.47) 85.73 (50.92) 81.26 (46.45) 79.52 (45.76) 0.1385
Total cholesterol, mg/dL, m(sd) 200.99 (41.42) 196.76 (44.11) 197.75 (40.40) 201.23 (46.55) 0.156
Urinary creatinine, mg/dL, m(sd) 143.25 (84.19) 137.66(85.69) 128.34 (83.36) 127.70 (80.33) 0.0015
 23 
Table 2: Means and standard deviations of Lean Mass, Fat Mass, % Body Fat and covariates 
according to creatinine standardized urinary phthalate metabolite quartiles mEP (mono-ethyl 
phthalate) 
  
Q1 (n=1,358) Q2 (n=1,358) Q3 (n=1,358) Q4 (n=1,357) p-value
urinary BPA,  μg/g creatinine <50.34 50.34-119.09 119.10-317.25 >317.25
Lean mass, gm (sd) 52,348.62 (12,431.54) 49,915.20 (12,976.91) 49,462.56 (11,876.04) 50,208.36 (12,311.00) <0.001
Fat mass, gm (sd) 27,257.89 (11,399.70) 28,254.48 (12,024.26) 27,869.15 (11,256.42) 29,250.88 (12,240.59) <0.001
Body fat, % (sd) 32.61 (8.83) 32.59 (8.46) 34.46 (8.93) 35.12 (8.80) <0.001
Gender, n(%)
Male
Female
855 (62.96)
503 (37.04)
628 (46.24)
730 (53.76)
622 (45.80)
736 (54.20)
648 (47.75)
709 (52.25)
<0.001
Age, years, m(sd) 49.91 (18.57) 48.41 (18.28) 48.02 (17.97) 49.12 (17.28) 0.0335
BMI, kg/m2, m(sd) 28.08 (6.07) 28.34 (6.49) 28.24 (5.99) 29.04 (6.51) 0.0004
Height, cm, m(sd) 169.89 (9.88) 167.48 (10.34) 167.12 (10.11) 166.82 (10.10) <0.0001
Weight, kg, m(sd) 82.33 (20.08) 79.81 (20.72) 79.02 (18.61) 81.11 (20.33) 0.0084
Waist circumference, cm, m(sd) 97.87 (15.20) 96.72 (15.69) 96.05 (14.39) 98.25 (15.54) 0.0012
Race/ethnicity, n(%)
Mexican American
Other Hispanic
Non-Hispanic White
Non-Hispanic Black
Other/Multi-ethnic
228 (16.79)
38 (2.80)
802 (59.06)
212 (15.61)
78 (5.74)
274 (20.18)
60 (4.42)
713 (52.50)
273 (20.10)
38 (2.80)
338 (24.89)
63 (4.64)
607 (44.70)
313 (23.05)
37 (2.72)
340 (25.06)
80 (5.90)
562 (41.41)
337 (24.83)
38 (2.80)
<0.001
Income, n(%)
$0 - $9,999 
$10,000 - $19,999
$20,000 - $34,999  
$35,000 - $54,999
$55,000 - $74,999
$75,000 + 
149 (11.88)
219 (17.46)
273 (21.77)
208 (16.59)
132 (10.53)
273 (21.77)
141 (11.24)
226 (18.01)
285 (22.71)
223 (17.77)
133 (10.60)
247 (19.68)
135 (10.60)
231 (18.13)
297 (23.31)
254 (19.94)
135 (10.60)
222 (17.43)
129 (10.39)
261 (21.01)
295 (23.75)
222 (17.87)
125 (10.06)
210 (16.91)
0.1050
Education, n(%)
Below High School
High School Diploma
Above High School 
377 (27.86)
300 (22.17)
676 (49.96)
387 (28.50)
327 (24.08)
644 (47.42)
432 (31.88)
316 (23.32)
607 (44.80)
471 (34.71)
317 (23.36)
569 (41.93)
<0.001
Marital status, n(%)
Married
Widowed
Divorced
Separated
Never married
Living with partner
784 (58.81)
109 (8.18)
111 (8.33)
38 (2.85)
215 (16.13)
76 (5.70)
703 (53.66)
122 (9.31)
120 (9.16)
44 (3.36)
240 (18.32)
81 (6.18)
735 (55.43)
125 (9.43)
134 (10.11)
45 (3.39)
210 (15.84)
77 (5.81)
739 (55.82)
111 (8.38)
146 (11.03)
51 (3.85)
215 (16.24)
62 (4.68)
0.2290
Moderate physical activity, n(%) 640 (47.13) 630 (46.43) 656 (48.38) 594 (43.84) 0.1120
Vigorous physical activity, n(%) 430 (31.66) 414 (30.51) 422 (31.12) 399 (29.42) 0.6220
Smoking status, n(%)
Never
Past
Current
677 (49.93)
325 (23.97)
354 (26.11)
699 (51.51)
356 (26.23)
302 (22.25)
729 (53.80)
323 (23.84)
303 (22.36)
674 (49.67)
348 (25.64)
335 (24.69)
0.0820
Diabetes, n(%)
Yes
Borderline
134 (9.88)
21 (1.55)
121 (8.91)
26 (1.91)
135 (9.94)
10 (0.74)
127 (9.37)
23 (1.70)
0.1650
Hypertension, n(%) 440 (34.76) 447 (35.06) 426 (33.31) 469 (37.10) 0.2520
Alcohol consumption 
(#drinks/month in past year), m(sd)
4.57 (7.89) 3.82 (6.91) 4.05 (7.22) 3.85 (6.82) 0.2085
Total calorie intake, kcal, m(sd) 2,190.91 (1,089.84) 2,113.57 (988.60) 2,136.28 (1,054.41) 2,094.69 (1,034.55) 0.0559
Total fat intake, gm, m(sd) 81.61 (52.60) 78.78 (45.33) 79.56 (48.29) 77.74 (45.73) 0.4382
Total cholesterol, mg/dL, m(sd) 201.10 (44.94) 202.51 (42.78) 201.25 (40.68) 201.04 (43.21) 0.7870
Urinary creatinine, mg/dL, m(sd) 135.97 (84.67) 133.76 (85.60) 135.68 (83.95) 131.87 (80.42) 0.5484
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Table 3: Means and standard deviations of Lean Mass, Fat Mass, % Body Fat and covariates 
according to creatinine standardized urinary phthalate metabolite quartiles mEHP (mono-2-ethyl-
hexyl phthalate) 
  
 
Q1 (n=1,359) Q2 (n=1,359) Q3 (n=1,359) Q4 (n=1,359) p-value
urinary BPA,  μg/g creatinine <1.29 1.29-2.67 2.68-5.61 >5.61
Lean mass, gm (sd) 52,574.75 (12,263.75) 50,231.92 (12,383.51) 49,065.75 (12,539.45) 50,022.63 (12,358.59) <0.001
Fat mass, gm (sd) 29,013.51 (11,873.93) 27,971.71 (11,511.11) 27,702.75 (11,750.71) 27,948.66 (11,847.01) <0.0184
Body fat, % (sd) 33.88 (8.78) 34.17 (8.79) 34.45 (8.82) 34.18 (8.84) <0.4209
Gender, n(%)
Male
Female
815 (59.97)
544 (40.03)
678 (49.89)
681 (50.11)
623 (45.84)
736 (54.16)
638 (46.95)
721 (53.05)
<0.001
Age, years, m(sd) 51.06 (17.98) 49.57 (18.47) 48.16 (17.67) 46.74 (17.79) <0.0001
BMI, kg/m2, m(sd) 28.98 (6.31) 28.29 (6.18) 28.11 (6.20) 28.33 (6.39) 0.0020
Height, cm, m(sd) 169.51 (9.92) 167.75 (10.15) 166.62 (9.99) 167.39 (10.42) <0.0001
Weight, kg, m(sd) 82.15 (20.10) 83.34 (19.89) 79.87 (19.59) 78.40 (20.14) <0.0001
Waist circumference, cm, m(sd) 99.57 (15.09) 97.16 (15.02) 95.61 (15.02) 96.54 (15.28) <0.0001
Race/ethnicity, n(%)
Mexican American
Other Hispanic
Non-Hispanic White
Non-Hispanic Black
Other/Multi-ethnic
299 (22.00)
46 (3.38)
689 (50.70)
281 (20.68)
44 (3.24)
282 (20.75)
51 (3.75)
680 (50.04)
287 (21.12)
59 (4.34)
314 (23.11)
72 (5.30)
654 (48.12)
271 (19.94)
48 (3.53)
286 (21.04)
72 (5.30)
665 (48.93)
295 (21.78)
40 (2.94)
0.1170
Income, n(%)
$0 - $9,999 
$10,000 - $19,999
$20,000 - $34,999  
$35,000 - $54,999
$55,000 - $74,999
$75,000 + 
130 (10.21)
259 (20.35)
287 (22.55)
234 (18.38)
138 (10.84)
225 (17.67)
147 (11.76)
212 (16.96)
295 (23.60)
229 (18.32)
120 (9.60)
247 (19.76)
132 (10.45)
238 (18.84)
292 (23.12)
234 (18.53)
140 (11.08)
227 (17.97)
146 (11.75)
228 (18.34)
278 (22.37)
210 (16.89)
128 (10.30)
253 (20.35)
0.5980
Education, n(%)
Below High School
High School Diploma
Above High School 
417 (30.71)
346 (25.48)
595 (43.81)
412 (30.32)
294 (21.63)
653 (48.05)
443 (32.69)
305 (22.51)
607 (44.80)
396 (29.20)
315 (23.23)
645 (47.57)
0.0780
Marital status, n(%)
Married
Widowed
Divorced
Separated
Never married
Living with partner
782 (58.66)
110 (8.25)
141 (10.58)
29 (2.18)
199 (14.93)
72 (5.40)
725 (55.05)
138 (10.48)
113 (8.58)
50 (3.80)
214 (16.25)
77 (5.85)
739 (56.28)
118 (8.99)
130 (9.90)
48 (3.66)
207 (15.77)
71 (5.41)
718 (53.78)
101 (7.57)
128 (9.59)
51 (3.82)
260 (19.48)
77 (5.77)
0.0110
Moderate physical activity, n(%) 645 (47.46) 628 (46.24) 617 (45.47) 631 (46.50) 0.7750
Vigorous physical activity, n(%) 975 (71.74)
 
930 (68.43)
 
948 (69.86)
 ( )
913 (67.28)
 
0.0690
Smoking status, n(%)
Never
Past
Current
645 (47.50)
370 (27.25)
343 (25.226)
695 (51.22)
359 (26.46)
303 (22.33)
714 (52.62)
314 (23.14)
329 (24.24)
727 (53.53)
311 (22.90)
320 (23.56)
0.0120
Diabetes, n(%)
Yes
Borderline
140 (10.31)
23 (1.69)
106 (7.81)
20 (1.47)
120 (8.84)
19 (1.40)
151 (11.12)
19 (1.40)
0.0860
Hypertension, n(%) 772 (60.69) 466 (36.55) 418 (32.76) 402 (31.75) <0.001
Alcohol consumption 
(#drinks/month in past year), m(sd)
4.41 (7.63) 4.05 (7.27) 3.96 (6.95) 3.88 (7.02) 0.6500
Total calorie intake, kcal, m(sd) 2,097.97 (982.66) 2,128 (1,038.31) 2,127.41 (1,088.85) 2,180.86 (1,057.25) 0.3279
Total fat intake, gm, m(sd) 78.04 (45.13) 78.75 (47.90) 79.78 (52.57) 81.10 (46.33) 0.2205
Total cholesterol, mg/dL, m(sd) 202.52 (43.67) 201.88 (42.56) 202.84 (43.64) 198.68 (41.68) 0.0561
Urinary creatinine, mg/dL, m(sd) 152.32 (80.81) 131.24 (87.48) 125.26 (83.89) 128.48 (79.58) 0.0001
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Table 4: Means and standard deviations of Lean Mass, Fat Mass, % Body Fat and covariates 
according to creatinine standardized urinary phthalate metabolite quartiles mBP (mono-n-butyl-
phthalate) 
  
 
Q1 (n=1,359) Q2 (n=1,360) Q3 (n=1,358) Q4 (n=1,359) p-value
urinary BPA,  μg/g creatinine <10.63 10.63-17.85 17.86-30.46 >30.46
Lean mass, gm (sd) 54,244.93 (12,216.55) 52,163.99 (12,557.14) 49,442.78 (12,122.88) 46,041.35 (11,343.38) <0.001
Fat mass, gm (sd) 27,494.85 (11,233.42) 28,292.54 (11,749.51) 28,703.40 (12,400.86) 28,146.15 (11,583.56) <0.1423
Body fat, % (sd) 32.06 (8.61) 33.55 (8.67) 34.93 (8.77) 36.14 (8.65) <0.001
Gender, n(%)
Male
Female
920 (67.70)
439 (32.30)
790 (58.09)
570 (41.91)
612 (45.07)
746 (54.93)
432 (31.79)
927 (68.21)
<0.001
Age, years, m(sd) 48.34 (17.57) 47.81 (17.92) 48.51 (18.20) 50.89 (18.36) <0.0001
BMI, kg/m2, m(sd) 28.47 (5.78) 28.73 (6.24) 28.54 (6.69) 27.99 (6.36) 0.0057
Height, cm, m(sd) 171.09 (9.90) 169.04 (10.00) 166.92 (9.94) 164.23 (9.58) <0.0001
Weight, kg, m(sd) 83.51 (19.27) 82.22 (20.03) 79.76 (20.46) 75.73 (19.20) <0.0001
Waist circumference, cm, m(sd) 98.44 (14.84) 98.15 (15.15) 96.89 (15.34) 95.39 (15.42) <0.0001
Race/ethnicity, n(%)
Mexican American
Other Hispanic
Non-Hispanic White
Non-Hispanic Black
Other/Multi-ethnic
290 (21.34)
35 (2.58)
720 (52.98)
263 (19.35)
51 (3.75)
301 (22.13)
53 (3.90)
700 (51.47)
273 (20.07)
33 (2.43)
300 (22.09)
60 (4.42)
646 (47.57)
306 (22.53)
46 (3.39)
290 (21.34)
93 (6.84)
622 (45.77)
293 (21.56)
61 (4.49)
<0.001
Income, n(%)
$0 - $9,999 
$10,000 - $19,999
$20,000 - $34,999  
$35,000 - $54,999
$55,000 - $74,999
$75,000 + 
103 (8.09)
191 (15.00)
285 (22.39)
253 (19.87)
137 (10.76)
304 (23.88)
129 (10.13)
212 (16.65)
290 (22.78)
218 (17.12)
152 (11.94)
272 (21.37)
140 (11.17)
243 (19.39)
312 (24.90)
232 (18.52)
126 (10.06)
200 (15.96)
183 (14.88)
291 (23.66)
265 (21.54)
204 (16.59)
111 (9.02)
176 (14.31)
<0.001
Education, n(%)
Below High School
High School Diploma
Above High School 
390 (28.74)
318 (23.43)
649 (47.83)
387 (28.46)
302 (22.21)
671 (49.34)
401 (29.59)
338 (24.94)
616 (45.46)
490 (36.14)
302 (22.27)
564 (41.59)
<0.001
Marital status, n(%)
Married
Widowed
Divorced
Separated
Never married
Living with partner
816 (61.08)
94 (7.04)
98 (7.34)
31 (2.32)
230 (17.22)
67 (5.01)
786 (59.23)
91 (6.86)
118 (8.89)
41 (3.09)
219 (16.50)
72 (5.43)
712 (53.65)
118 (8.89)
147 (11.08)
54 (4.07)
224 (16.88)
72 (5.43)
650 (49.69)
164 (12.54)
149 (11.39)
52 (3.98)
207 (15.83)
86 (6.57)
<0.001
Moderate physical activity, n(%) 641 (47.17) 676 (49.78) 632 (46.54) 572 (42.18) 0.0010
Vigorous physical activity, n(%) 485 (35.69) 446 (32.82) 396 (29.16) 339 (25.00) <0.001
Smoking status, n(%)
Never
Past
Current
725 (53.39)
380 (27.98)
253 (18.63)
692 (50.92)
344 (25.31)
323 (23.77)
691 (50.96)
338 (24.93)
327 (24.12)
673 (49.59)
292 (21.52)
392 (28.89)
<0.001
Diabetes, n(%)
Yes
Borderline
115 (8.47)
26 (1.91)
116 (8.54)
21 (1.55)
130 (9.57)
13 (0.96)
156 (11.49)
21 (1.55)
0.0350
Hypertension, n(%) 453 (35.70) 439 (34.24) 425 (33.62) 469 (36.81) 0.3260
Alcohol consumption 
(#drinks/month in past year), m(sd)
4.28 (7.21) 4.36 (7.54) 4.08 (7.26) 3.56 (6.84) 0.0034
Total calorie intake, kcal, m(sd) 2,254.08 (1,042.39) 2,196.81 (1,036.59) 2,094.63 (1,034.73) 1,986.12 (1,037.24) <0.0001
Total fat intake, gm, m(sd) 84.19 (47.88) 82.24 (49.00) 77.94 (46.21) 73.20 (48.41) <0.0001
Total cholesterol, mg/dL, m(sd) 202.31 (42.79) 199.73 (42.45) 202.84 (43.13) 201.09 (43.29) 0.2590
Urinary creatinine, mg/dL, m(sd) 129.55 (86.55) 144.69 (83.18) 134.99 (82.59) 128.05 (81.25) <0.0001
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Table 5: Means and standard deviations of Lean Mass, Fat Mass, % Body Fat and covariates 
according to creatinine standardized urinary phthalate metabolite quartiles mBzP (mono-benzyl-
phthalate) 
 
 
 
Q1 (n=1,359) Q2 (n=1,360) Q3 (n=1,358) Q4 (n=1,359) p-value
urinary mBzP,  μg/g creatinine <4.35 4.35-7.74 7.75-14.01 <14.01
Lean mass, gm, m(sd) 51,762.21 (12,454.52) 50,893.48 (12,179.48) 50,052.44 (12,537.41) 49,186.93 (12,492.92) <0.001
Fat mass, gm, m(sd) 27,391.43 (10,755.54) 27,769.01 (11,657.82) 28,204.49 (11,752.60) 29,271.70 (12,698.52) <0.003
%Body fat, m(sd) 33.15 (8.51) 33.66 (8.81) 34.40 (8.78) 35.48 (8.95) <0.001
Gender, n(%)
Male
Female
795 (58.50)
564 (41.50)
721 (53.05)
638 (46.95)
652 (47.98)
707 (52.02)
586 (43.12)
773 (56.88)
<0.001
Age, years, m(sd) 50.37 (17.47) 48.66 (17.84) 48.06 (18.10) 48.45 (18.69) 0.0044
BMI, kg/m^2, m(sd) 28.17 (5.72) 28.37 (6.19) 28.34 (6.30) 28.85 (6.84) 0.3198
Height, cm, m(sd) 169.14 (10.07) 168.15 (10.18) 167.66 (10.21) 166.32 (10.04) <0.0001
Weight, kg, m(sd) 80.90 (19.04) 80.34 (19.51) 79.90 (20.10) 80.09 (21.15) 0.179
Waist circumference, cm, m(sd) 97.47 (14.52) 96.84 (15.22) 96.76 (15.26) 97.82 (15.89) 0.1968
Race/ethnicity, n(%)
Mexican American
Other Hispanic
Non-Hispanic White
Non-Hispanic Black
Other/Multi-ethnic
327 (24.06)
53 (3.90)
664 (48.86)
262 (19.28)
53 (3.90)
297 (21.85)
59 (4.34)
642 (47.24)
304 (22.37)
57 (4.19)
295 (21.71)
65 (4.78)
689 (50.70)
272 (20.01)
38 (2.80)
262 (19.28)
64 (4.71)
693 (50.99)
297 (21.85)
43 (3.16)
0.0630
Income, n(%)
$0 - $9,999 
$10,000 - $19,999
$20,000 - $34,999  
$35,000 - $54,999
$55,000 - $74,999
$75,000 + 
107 (8.47)
189 (14.95)
282 (22.31)
248 (19.62)
121 (9.57)
317 (25.08)
114 (9.13)
223 (17.87)
281 (22.52)
227 (18.19)
149 (11.94)
254 (20.35)
139 (10.96) 
254 (20.03)
291 (22.95)
228 (17.98)
132 (10.41)
224 (17.67)
195 (15.61)
271 (21.70)
298 (23.86)
204 (16.33)
124 (9.93)
157 (12.57)
<0.001
Education, n(%)
Below High School
High School Diploma (including 
GED) 
Above High School 
417 (30.71)
293 (21.58)
648 (47.72)
397 (29.23)
311 (22.90)
650 (47.86)
401 (29.55)
333 (24.54)
623 (45.91)
453 (33.43)
323 (23.84)
579 (42.73)
0.0470
Marital status, n(%)
Married
Widowed
Divorced
Seperated
Never married
Living with partner
819 (61.30)
110 (8.23)
93 (6.96)
36 (2.69)
220 (16.47)
58 (4.34)
754 (56.91)
114 (8.60)
130 (9.81)
40 (3.02)
202 (15.25)
85 (6.42)
713 (53.93)
114 (8.62)
133 (10.06)
46 (3.48)
242 (18.31)
74 (5.60)
678 (51.56)
129 (9.81)
156 (11.86)
56 (4.26)
216 (16.43)
80 (6.08)
<0.001
Mod. physical activity, n(%) 636 (46.83) 634 (43.72) 652 (48.05) 599 (44.08) 0.2050
Vig. physical activity, n(%) 434 (31.96) 428 (31.54) 423 (31.15) 381 (28.04) 0.1060
Smoking status, n(%)
Never
Past
Current
713 (52.50)
382 (28.13)
263 (19.37)
730 (53.72)
326 (23.99)
303 (22.30)
691 (50.88)
321 (23.64)
346 (25.48)
647 (47.75)
325 (23.99)
383 (28.27)
<0.001
Diabetes, n(%)
Yes
Borderline
121 (8.92)
18 (1.33)
134 (9.86)
22 (1.62)
124 (9.13)
21 (1.55)
138 (10.16)
20 (1.47)
0.9080
Hypertension, n(%) 473 (37.51) 428 (33.44) 423 (33.12) 462 (36.35) 0.0500
Alcohol consumption (#drinks/month 
in past year), m(sd)
4.35 (7.57) 4.09 (7.04) 3.84 (7.09) 4.01 (7.18) 0.2074
Total calorie intake, kcal, m(sd) 2,146.90 (1,007.86) 2,160.20 (985.91) 2,137.78 (1,044.60) 2,088.73 (1,126.48) 0.0194
Total fat intake, gm, m(sd) 78.94 (45.81) 81.01 (47.46) 79.64 (46.10) 78.06 (52.61) 0.1059
Total cholesterol, mg/dL, m(sd) 202.04 (40.37) 201.10 (42.97) 201.29 (41.30) 201.55 (46.81) 0.6397
Urinary creatinine, mg/dL, m(sd) 119.51 (79.46) 135.98 (83.66) 139.92 (83.87) 141.88 (85.70) 0.0001
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Table 6: Adjusted regression coefficients, standard errors and p-values for Lean Mass by urinary 
BPA and phthalate metabolites 
 
 
 
 
Urinary BPA or phthalte 
metabolite concentration (μg/g 
creatinine)
N Model 1
beta (se)
p-value N Model 2
beta (se)
p-value N Model 3
beta (se)
p-value
Bisphenol-A (BPA) 2,533 2,519 2,166
continuous -19.81 (17.07) 0.246 -21.51 (10.31) 0.037 -16.35 (9.97) 0.101
Q1: <1.15 (ref) _ (ref) _ (ref) _
Q2: 1.15-2.00 1,154.85 (524.14) 0.028 -138.56 (321.85) 0.667 -38.42 (321.41) 0.905
Q3: 2.01-3.37 868.84 (546.23) 0.112 -398.97 (333.83) 0.232 -150.25 (330.43) 0.649
Q4: >3.37 15.12 (584.92) 0.979 -1,263.23 (356.77 <0.001 -862.16 (354.65) 0.015
p-trend: 0.872 p-trend: <0.001 p-trend: <0.017
Monoethyl phthalate (mEP) 5,431 5,378 4,531
continuous 0.05 (0.09) 0.585 -0.04 (0.05) 0.471 -0.04 (0.06) 0.422
Q1: <50.34 (ref) _ (ref) _ (ref) _
Q2: 50.34-119.09 496.34 (338.49) 0.146 34.38 (207.65) 0.869 -56.17 (204.72) 0.784
Q3: 119.10-317.25 -56.14 (351.69) 0.873 -321.22 (215.34) 0.136 -355.63 (213.58) 0.096
Q4: >317.25 887.91 (363.87) 0.015 -414.95 (222.68) 0.062 -393.14 (221.49) 0.076
p-trend: 0.067 p-trend: 0.022 p-trend: 0.035
Monobutyl phthalate (mBP) 5,436 5,383 4,535
continuous -0.50 (0.60) 0.407 -0.32 (0.37) 0.379 -0.21 (0.34) 0.531
Q1: <10.63 (ref) _ (ref) _ (ref) _
Q2: 10.63-17.85 -82.34 (344.03) 0.811 -98.73 (212.80) 0.643 -382.42 (207.22) 0.065
Q3:17.86-30.46 -741.61 (372.95) 0.047 -680.65 (228.83) 0.003 -823.58 (226.84) <0.001
Q4: >30.46 -1,319.47 (404.05) 0.001 -881.64 (246.48) <0.001 -731.76 (248.89) 0.003
p-trend: <0.001 p-trend: <0.001 p-trend: <0.001
Monoethylhexyl phthalate 
(mEHP)
5,436 5,383 4,535
continuous -1.04 (2.92) 0.721 1.56 (1.83) 0.396 0.45 (1.74) 0.796
Q1: <1.29 (ref) _ (ref) _ (ref) _
Q2: 1.29-2.67 -369.59 (340.02) 0.277 -143.83 (208.24) 0.490 -175.79 (204.79) 0.391
Q3: 2.68-5.61 -217.82 (336.35) 0.517 12.72 (206.85) 0.951 -142.57 (207.20) 0.491
Q4: >5.61 -401.54 (353.52) 0.256 -87.67 (217.68) 0.687 -130.65 (149.82) 0.545
p-trend: 0.326 p-trend: 0.842 p-trend: <0.568
Monobenzyl phthalate (mBzP) 5,436 5,383 4,535
continuous -0.50 (0.60) 0.407 -0.27 (0.31) 0.387 -0.05 (0.29) 0.858
Q1: <4.35 (ref) _ (ref) _ (ref) _
Q2: 4.35-7.74 524.67 (342.31) 0.125 30.22 (209.76) 0.885 -97.74 (208.71) 0.640
Q3: 7.75-14.01 123.43 (369.01) 0.738 -592.98 (226.46) 0.009 -706.35 (223.25) 0.002
Q4: <14.01 0.96 (405.25) 0.998 -1,070.43 (248.06 <0.001 -909.13 (252.32) <0.001
p-trend: 0.709 p-trend: <0.001 p-trend: <0.001
Model 3 (mEP): creatinine, age, gender, race, BMI, family income, education, moderate physical activity, vigorous physical activity, WC, total calorie intake, 
serum cholesterol
Model 3 (mBP): creatinine, age, gender, race, BMI, family income, eduation, moderate physical activity, vigorous physical activity, WC, total calorie intake, 
serum cholesterol
Model 3 (mEHP): creatinine, age, gender, race, BMI, family income, education, moderate physical activity, vigerous physical activity, WC, total calorie 
intake, serum cholesterol
Model 3 (mBzP): creatinine, age, gender, race, BMI, family income, eduation, moderate physical activity, vigorous physical activity, WC, total calorie intake, 
serum cholesterol 
Model 1: creatinine, age, gender, race
Model 2: creatinine, age, gender, race, BMI
Model 3 (BPA): creatinine, age, gender, race, BMI, family income, vigorous physical activity, moderate physical activity, WC, total calorie intake, serum 
cholesterol
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Table 7: Adjusted regression coefficients, standard errors and p-values for Fat Mass by urinary 
BPA and phthalate metabolites 
 
 
 
 
 
Urinary BPA or phthalte 
metabolite concentration (μg/g 
creatinine)
N Model 1
beta (se)
p-value N Model 2
beta (se)
p-value N Model 3
beta (se)
p-value
Bisphenol-A (BPA) 2,533 2,519 2,368
continuous -1.42 (21.61) 0.948 -3.35 (7.15) 0.639 -4.34 (6.53) 0.507
Q1: <1.15 (ref) _ (ref) _ (ref) _
Q2: 1.15-2.00 2,243 (661.18) 0.001 349.20 (231.34) 0.132 123.02 (209.12) 0.557
Q3: 2.01-3.37 2,150.24 (688.93) 0.001 381.87 (235.59) 0.105 232.05 (212.90) 0.276
Q4: >3.37 2,106.20 (736.83) 0.004 303.09 (249.06) 0.224 236.58 (232.89) 0.310
p-trend: 0.009 p-trend: 0.248 p-trend: <0.276
Monoethyl phthalate (mEP) 5,431 5,378 4,754 
continuous 0.13 (0.12) 0.275 0.13 (0.12) 0.275 -0.01 (0.08) 0.696
Q1: <50.34 (ref) _ (ref) _ (ref) _
Q2: 50.34-119.09 753.03 (442.00) 0.089 -22.82 (150.36) 0.879 -73.38 (139.89) 0.600
Q3: 119.10-317.25 587.42 (456.46) 0.198 97.70 (152.98) 0.523 170.28 (143.26) 0.235
Q4: >317.25 1,995.70 (474.43) <0.001 -98.92 (158.69) 0.533 -37.67 (149.82) 0.801
p-trend: <0.001 p-trend: <0.714 p-trend: <0.779
Monobutyl phthalate (mBP) 5,436 5,383 4,759
continuous -0.24 (0.79) 0.761 0.04 (0.26) 0.862
0.02 (0.23) 0.922
Q1: <10.63 (ref) _ (ref) _ (ref) _
Q2: 10.63-17.85 27.48 (447.99) 0.951 -11.88 (152.12) 0.938 -209.39 (141.21) 0.138
Q3:17.86-30.46 -50.57 (438.48) 0.917 -51.16 (164.89) 0.756 -66.30 (152.79) 0.664
Q4: >30.46 -785.98 (526.48) 0.136 -144.10 (174.60) 0.409 -48.73 (169.65) 0.774
p-trend: <0.141 p-trend: 0.495 p-trend: <0.984
Monoethylhexyl phthalate 
(mEHP)
5,436 5,383 4,886
continuous -2.35 (3.80) 0.537 1.33 (1.30) 0.308 0.55 (1.21) 0.646
Q1: <1.29 (ref) _ (ref) _ (ref) _
Q2: 1.29-2.67 -429.28 (443.00) 0.333 -130.98 (146.75) 0.372 -78.01 (136.91) 0.569
Q3: 2.68-5.61 -630.09 (438.41) 0.151 -303.11 (148.78) 0.042 -319.91 (140.90) 0.023
Q4: >5.61 -806.72 (459.64) 0.079 -394.87 (155.61) 0.011 -297.98 (144.87) 0.040
p-trend: <0.072 p-trend: <0.007 p-trend: <0.016
Monobenzyl phthalate (mBzP) 5,436 5,383 4,759
continuous -0.24 (0.79) 0.761 0.22 (0.22) 0.322 0.21 (0.20) 0.298
Q1: <4.35 (ref) _ (ref) _ (ref) _
Q2: 4.35-7.74 714.00 (446.00) 0.109 -48.69 (147.28) 0.741 -143.55 (140.19) 0.306
Q3: 7.75-14.01 1,070.98 (479.96) 0.026 -95.71 (161.13) 0.553 -41.62 (152.15) 0.784
Q4: <14.01 1,771.72 (529.45) 0.001 69.25 (174.92) 0.692 48.51 (167.10) 0.772
p-trend: <0.001 p-trend: <0.764 p-trend: <0.611
Model 3 (mEHP): creatinin, age, gender, race, BMI, education, vigorous physical activity, diabetes, WC, alcohol intake, total calorie intake, total fat intake
Model 3 (mBzP): creatinine, age, gender, race, BMI, education, marital status, vigorous physical activity, diabetes, WC, alcohol intake, total calorie intake, total 
fat intake
Model 1: creatinine, age, gender, race
Model 2: creatinine, age, gender, race, BMI
Model 3 (BPA): creatinine, age, gender, race, BMI, education, diabetes, waist circumference, total calorie intake, total fat intake
Model 3 (mBP): creatinine, age, gender, race, BMI, marital status, vigorous physical activity, diabetes, WC, alcohol intake, total calorie intake, total fat intake
Model 3 (mEP): creatinine, age, gender, race, BMI, education, marital status, vigorous physical activity, diabetes, WC, alcohol intake, total calorie intake, total 
fat intake
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Table 8: Adjusted regression coefficients, standard errors and p-values for % Body Fat by urinary 
BPA and phthalate metabolites 
 
 
  
Urinary BPA or phthalte 
metabolite concentration (μg/g 
creatinine)
N Model 1
beta (se)
p-value N Model 2
beta (se)
p-value N Model 3
beta (se)
p-value
Bisphenol-A (BPA) 2,533 2,519 2,256
continuous 0.005 (0.01) 0.631 0.005(0.007) 0.503 0.001 (0.07) 0.838
Q1: <1.15 (ref) _ (ref) _ (ref) _
Q2: 1.15-2.00 1.26 (0.37) 0.001 0.45 (0.24) 0.062 0.27 (0.24) 0.259
Q3: 2.01-3.37 1.29 (0.38) 0.001 0.50 (0.24) 0.039 0.40 (0.23) 0.085
Q4: >3.37 1.44 (0.40) <0.001 0.67 (0.26) 0.009 0.64 (0.25) 0.011
p-trend: <0.001 p-trend: 0.013 p-trend: 0.012
Monoethyl phthalate (mEP) 5,431 5,378 4,537
continuous <0.001 (<0.001) 0.420 <0.001 (<0.001) 0.875  - <0.001 (<0.001) 0.704
Q1: <50.34 (ref) _ (ref) _ (ref) _
Q2: 50.34-119.09 0.48 (0.24) 0.051 0.10 (0.15) 0.497 0.12 (0.15) 0.433
Q3: 119.10-317.25 0.65 (0.25) 0.009 0.41 (0.16) 0.010 0.49 (0.16) 0.002
Q4: >317.25 1.16 (0.26) <0.001 1.19 (0.16) 0.225 0.27 (0.16) 0.093
p-trend: <0.001 p-trend: 0.085 p-trend: 0.022
Monobutyl phthalate (mBP) 5,436 5,383 4,542
continuous <0.001 (<0.001) 0.790 <0.001 (<0.001) 0.341 <0.001 (<0.001) 0.420
Q1: <10.63 (ref) _ (ref) _ (ref) _
Q2: 10.63-17.85 0.11 (0.25) 0.647 0.10 (0.16) 0.534 0.10 (0.15) 0.490
Q3:17.86-30.46 0.30 (0.27) 0.264 0.35 (0.17) 0.044 0.43 (0.17) 0.011
Q4: >30.46 -0.17 (0.29) 0.552 0.12 (0.18) 0.492 0.38 (0.18) 0.039
p-trend: 0.688 p-trend: 0.301 p-trend: 0.014
Monoethylhexyl phthalate 
(mEHP)
5,436 5,383
4,540 
continuous - <0.001 (0.002) 0.793 0.001 (0.001) 0.426 <0.001 (0.001) 0.480
Q1: <1.29 (ref) _ (ref) _ (ref) _
Q2: 1.29-2.67 -0.19 (0.24) 0.439 -0.07 (0.15) 0.642 -0.3 (0.15) 0.828
Q3: 2.68-5.61 -0.23 (0.24) 0.349 -0.07 (0.15) 0.669 -0.04 (0.15) 0.800
Q4: >5.61 -0.42 (0.25) 0.095 -0.24 (0.16) 0.136 -0.12 (0.16) 0.437
p-trend: 0.104 p-trend: 0.164 p-trend: 0.465
Monobenzyl phthalate (mBzP) 5,436 5,383 4,542
continuous <0.001 0.790 <0.001 (<0.001) 0.143 <0.001 (<0.001) 0.280
Q1: <4.35 (ref) _ (ref) _ (ref) _
Q2: 4.35-7.74 0.41 (0.24) 0.091 0.06 (0.15) 0.702 0.05 (0.15) 0.718
Q3: 7.75-14.01 0.70 (0.26) 0.008 0.16 (0.16) 0.338 0.38 (0.16) 0.020
Q4: <14.01 1.20 (0.29) <0.001 0.43 (0.18) 0.015 0.61 (0.18) 0.001
p-trend: <0.001 p-trend: 0.013 p-trend: <0.001
Model 3 (mBzP): creatinine, age, gender, race, BMI, marital status, vigorous physical activity, smoking status, diabetes, WC, alcohol intake, total calorie intake, 
serum cholesterol
Model 3 (mEHP): creatinine, age, gender, race, BMI, education, marital status, vigorous physical activity, smoking status, diabetes, WC, alcohol intake, total 
calorie intake, serum cholesterol
Model 1: creatinine, age, gender, race
Model 2: creatinine, age, gender, race, BMI
Model 3 (BPA): creatinine, age, gender, race, BMI, vigorous physical activity, education, smoking status, diabetes, WC, total calorie intake, serum cholesterol
Model 3 (mEP): creatinine, age, gender, race, BMI, marital status, vigorous physical activity, smoking status, diabetes, WC, alcohol intake, total calorie intake, 
serum cholsterol 
Model 3 (mBP): creatinine, age, gender, race, BMI, marital status, vigorous physical activity, smoking status, diabetes, WC, alcohol intake, total calorie intake, 
serum cholesterol
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Table 9: Regression coefficients of fully adjusted Lean Mass models* stratified by BMI category 
 
Urinary BPA or phthalte metabolite 
concentration (μg/g creatinine)
N b (se) p-value N b (se) p-value N b (se) p-value
Bisphenol-A (BPA) 679 726 761
Q1: <1.15 (ref) _ (ref) _ (ref) _
Q2: 1.15-2.00 -740.46 (0.124) 0.124 232.86 (523.77) 0.657 124.00 (666.30) 0.852
Q3: 2.01-3.37 -813.32 (55.22) 0.108 554.97 (567.68) 0.329 -553.00 (656.67) 0.400
Q4: >3.37 -1,530.16 (540.89) 0.005 -310.32 (611.33) 0.612 -756.20 (691.77) 0.275
p-trend: 0.007 p-trend: 0.765 p-trend: 0.161
Monoethyl phthalate (mEP) 1,374 1,584 1,550
Q1: <50.34 (ref) _ (ref) _ (ref) _
Q2: 50.34-119.09 -2.08 (323.96) 0.995 160.90 (338.71) 0.635 -660.34 (411.63) 0.109
Q3: 119.10-317.25 45.66 (333.89) 0.891 -190.18 (354.37) 0.592 -858.19 (426.84) 0.045
Q4: >317.25 77.40 (367.52) 0.833 -219.18 (368.51) 0.552 -879.56 (417.55) 0.035
p-trend: 0.811 p-trend: 0.373 p-trend: 0.045
Monobutyl phthalate (mBP) 1,398 1,587 1,550
Q1: <10.63 (ref) _ (ref) _ (ref) _
Q2: 10.63-17.85 -579.56 (327.40) 0.077 4.68 (335.95) 0.989 -940.24 (418.26) 0.025
Q3:17.86-30.46 -1,110.82 (369.08) 0.003 -569.99 (364.91) 0.113 -1,054.40 (444.10) 0.018
Q4: >30.46 -807.06 (393.80) 0.041 -588.78 (418.30) 0.159 -1,170.24 (481.35) 0.015
p-trend: 0.022 p-trend: 0.076 p-trend: 0.026
Monoethylhexyl phthalate (mEHP) 1,398 1,587 1,550
Q1: <1.29 (ref) _ (ref) _ (ref) _
Q2: 1.29-2.67 189.35 (322.91) 0.558 195.92 (344.63) 0.570 -595.14 (407.94) 0.145
Q3: 2.68-5.61 312.38 (337.24) 0.354 180.53 (337.86) 0.593 -997.75 (393.57) 0.011
Q4: >5.61 263.50 (351.11) 0.453 52.27 (359.87) 0.885 -635.22 (414.12) 0.125
p-trend: 0.403 p-trend: 0.863 p-trend: 0.074
Monobenzyl phthalate (mBzP) 1,375 1,587 1,550
Q1: <4.35 (ref) _ (ref) _ (ref) _
Q2: 4.35-7.74 -325.79 (320.39) 0.309 289.71 (337.27) 0.390 -452.16 (436.16) 0.037
Q3: 7.75-14.01 -1,002.26 (360.00) 0.005 -280.54 (366.97) 0.445 -927.89 (444.14) 0.001
Q4: <14.01 -714.87 (407.35) 0.080 -681.00 (416.25) 0.102 -1,651.46 (485.29) <0.001
p-trend: 0.025 p-trend: 0.047 p-trend: <0.001
Model 3 (mbp): creatinine, age, gender, race, family income, eduation, moderate physical activity, vigorous physical activity, WC, total calorie intake, serum cholesterol
Model 3 (mehp): creatinine, age, gender, race, family income, education, moderate physical activity, vigerous physical activity, WC, total calorie intake, serum cholesterol
Model 3 (model): creatinine, age, gender, race, family income, eduation, moderate physical activity, vigorous physical activity, WC, total calorie intake, serum cholesterol 
BMI <24.99 kg/m^2 BMI 25-29.99 kg/m^2 BMI >30 kg/m^2
*Model 3 (BPA): creatinine, age, gender, race, family income, vigorous physical activity, moderate physical activity, WC, total calorie intake, serum cholesterol
Model 3 (mep): creatinine, age, gender, race, family income, education, moderate physical activity, vigorous physical activity, WC, total calorie intake, serum cholesterol
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Table 10: Regression coefficients of fully adjusted Fat Mass models* stratified by BMI category 
 
Urinary BPA or phthalte metabolite 
concentration (μg/g creatinine)
N b (se) p-value N b (se) p-value N b (se) p-value
Bisphenol-A (BPA) 728 797 825
Q1: <1.15 (ref) _ (ref) _ (ref) _
Q2: 1.15-2.00 315.17 (312.14) 0.314 100.77 (318.61) 0.752 -121.33 (579.40) 0.834
Q3: 2.01-3.37 479.47 (328.64) 0.146 -60.94 (341.62) 0.858 -23.77 (580.07) 0.967
Q4: >3.37 357.07 (346.29) 0.303 -59.97 (373.94) 0.873 329.36 (613.17) 0.591
p-trend: 0.246 p-trend: 0.762 p-trend: 0.533
Monoethyl phthalate (mEP) 1,492 1,651 1,611
Q1: <50.34 (ref) _ (ref) _ (ref) _
Q2: 50.34-119.09 107.24 (209.67) 0.609 162.01 (225.59) 0.473 -370.06 (410.78) 0.368
Q3: 119.10-317.25 306.33 (213.60) 0.152 648.25 (235.49) 0.006 -22.40 (416.41) 0.957
Q4: >317.25 219.42 (234.89) 0.350 218.82 (245.32) 0.373 239.66 (414.90) 0.564
p-trend: 0.220 p-trend: 0.150 p-trend: 0.343
Monobutyl phthalate (mBP) 1,493 1,655 1,611
Q1: <10.63 (ref) _ (ref) _ (ref) _
Q2: 10.63-17.85 -311.87 (212.35) 0.142 -118.16 (226.87) 0.603 -837.51 (406.54) 0.040
Q3:17.86-30.46 -407.64 (236.18) 0.085 65.45 (246.23) 0.790 39.87 (434.53) 0.927
Q4: >30.46 -107.76 (249.53) 0.666 97.75 (288.53) 0.735 -719.31 (472.48) 0.128
p-trend: 0.617 p-trend: 0.607 p-trend: 0.431
Monoethylhexyl phthalate (mEHP) 1,534 1,701 1,651
Q1: <1.29 (ref) _ (ref) _ (ref) _
Q2: 1.29-2.67 -218.69 (208.30) 0.294 -114.39 (232.46) 0.623 309.93 (394.42) 0.432
Q3: 2.68-5.61 -470.07 (218.42) 0.032 -93.17 (228.15) 0..683 -367.01 (381.78) 0.337
Q4: >5.61 -416.27 (221.72) 0.061 -316.55 (242.02) 0.191 119.80 (397.12) 0.763
p-trend: 0.034 p-trend: 0.234 p-trend: 0.867
Monobenzyl phthalate (mBzP) 1,493 1,655 1,611
Q1: <4.35 (ref) _ (ref) _ (ref) _
Q2: 4.35-7.74 -183.32 (204.06) 0.369 -134.56 (226.84) 0.553 -160.38 (418.25) 0.701
Q3: 7.75-14.01 -204.28 (232.49) 0.380 -287.61 (250.72) 0.252 287.75 (436.26) 0.510
Q4: <14.01 -487.25 (255.96) 0.057 -107.41 (284.03) 0.705 170.09 (463.36) 0.714
p-trend: 0.075 p-trend: 0.583 p-trend: 0.487
Model 3 (mbzp): creatinine, age, gender, race, education, marital status, vigorous physical activity, diabetes, WC, alcohol intake, total calorie intake, total fat intake
BMI <24.99 kg/m^2 BMI 25-29.99 kg/m^2 BMI >30 kg/m^2
*Model 3 (BPA): creatinine, age, gender, race, education, diabetes, WC, total calorie intake, total fat intake
Model 3 (mep): creatinine, age, gender, race, education, marital status, vigorous physical activity, diabetes,  WC, alcohol intake, total calorie intake, total fat intake
Model 3 (mbp): creatinine, age, gender, race, marital status, vigorous physical activity, diabetes, WC, alcohol intake, total calorie intake, total fat intake
Model 3 (mehp): creatinin, age, gender, race, education, vigorous physical activity, diabetes, WC, alcohol intake, total calorie intake, total fat intake
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Table 11: Regression coefficients of fully adjusted % Body Fat models* stratified by BMI category 
 
Urinary BPA or phthalte metabolite 
concentration (μg/g creatinine)
N b (se) p-value N b (se) p-value N b (se) p-value
Bisphenol-A (BPA) 705 758 793
Q1: <1.15 (ref) _ (ref) _ (ref) _
Q2: 1.15-2.00 0.58 (0.47) 0.217 -0.08 (0.34) 0.820 0.004 (0.38) 0.787
Q3: 2.01-3.37 0.74 (0.47) 0.116 -0.22 (0.38) 0.556 0.38 (0.37) 0.125
Q4: >3.37 0.89 (0.48) 0.066 -0.01 (0.40) 0.980 0.62 (0.40) 0.075
p-trend: 0.062 p-trend: 0.925 p-trend: 0.066
Monoethyl phthalate (mEP) 1,407 1,580 1,550
Q1: <50.34 (ref) _ (ref) _ (ref) _
Q2: 50.34-119.09 0.23 (0.29) 0.430 0.11 (0.24) 0.658 0.06 (0.25) 0.820
Q3: 119.10-317.25 0.26 (0.29) 0.370 0.71 (0.25) 0.005 0.41 (0.26) 0.111
Q4: >317.25 0.23 (0.32) 0.472 0.30 (0.26) 0.253 0.40 (0.25) 0.117
p-trend: 0.447 p-trend: 0.071 p-trend: 0.059
Monobutyl phthalate (mBP) 1,408 1,584 1,550
Q1: <10.63 (ref) _ (ref) _ (ref) _
Q2: 10.63-17.85 -0.07 (0.29) 0.800 0.17 (0.24) 0.756 0.09 (0.25) 0.709
Q3:17.86-30.46 0.14 (0.33) 0.672 0.53 (0.26) 0.047 0.50 (0.26) 0.059
Q4: >30.46 0.38 (0.35) 0.275 0.64 (0.31) 0.042 0.21 (0.29) 0.457
p-trend: 0.236 p-trend: 0.018 p-trend: 0.279
Monoethylhexyl phthalate (mEHP) 1,407 1,583 1,550
Q1: <1.29 (ref) _ (ref) _ (ref) _
Q2: 1.29-2.67 -0.47 (0.29) 0.102 -0.10 (0.25) 0.701 0.46 (0.25) 0.069
Q3: 2.68-5.61 -0.72 (0.30) 0.018 0.01 (0.24) 0.953 0.28 (0.24) 0.243
Q4: >5.61 -0.50 (0.30) 0.093 -0.17 (0.26) 0.512 0.23 (0.25) 0.362
p-trend: 0.057 p-trend: 0.624 p-trend: 0.468
Monobenzyl phthalate (mBzP) 1,408 1,584 1,550
Q1: <4.35 (ref) _ (ref) _ (ref) _
Q2: 4.35-7.74 0.03 (0.28) 0.922 -0.18 (0.24) 0.448 0.04 (0.25) 0.867
Q3: 7.75-14.01 0.29 (0.32) 0.362 0.10 (0.27) 0.709 0.48 (0.27) 0.071
Q4: <14.01 0.03 (0.36) 0.923 0.56 (0.30) 0.064 0.71 (0.28) 0.012
p-trend: 0.717 p-trend: 0.038 p-trend: 0.003
Model 3 (mehp): creatinine, age, gender, race, education, marital status, vigorous physical activity, smoking status, diabetes, WC, alcohol intake, total calorie intake, serum 
Model 3 (mbzp): creatinine, age, gender, race, marital status, vigorous physical activity, smoking status, diabetes, WC, alcohol intake, total calorie intake, serum cholesterol
*Model 3 (BPA):  creatinine, age, gender, race, vigorous physical activity, education, smoking status, diabetes, WC, total calorie intake, serum cholesterol
Model 3 (mep): creatinine, age, gender, race, marital status, vigorous physical activity, smoking status, diabetes, WC, alcohol intake, total calorie intake, serum cholsterol 
Model 3 (mbp): creatinine, age, gender, race, marital status, vigorous physical activity, smoking status, diabetes, WC, alcohol intake, total calorie intake, serum cholesterol
BMI <24.99 kg/m^2 BMI 25-29.99 kg/m^2 BMI >30 kg/m^2
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Table 12: Adjusted* regression coefficients, standard errors and p-values for Lean Mass, Fat Masss, and %Body Fat by urinary BPA and 
phthalate metabolites in sub-population of subjects with non-imputed DXA measures 
Urinary BPA or phthalte metabolite 
concentration (μg/g creatinine)
N Lean Mass
beta (se)
p-value N Fat Mass
beta (se)
p-value N %Body Fat
beta (se)
p-value
Bisphenol-A (BPA) 1,820 1,820 1.817
continuous -12.49 (14.27) 0.382 3.36 (17.33) 0.846 0.007 (0.01) 0.556
Q1: <1.15 (ref) _ (ref) _ (ref) _
Q2: 1.15-2.00 315.23 (488.80) 0.519 1,543.87 (591.92) 0.009 1.20 (0.38) 0.002
Q3: 2.01-3.37 34.45 (514.19) 0.947 1,318.08 (622.67) 0.034 1.19 (0.40) 0.003
Q4: >3.37 -24.93 (552.25) 0.964 1,975.74 (668.76) 0.003 1.55 (0.43) <0.001
p-trend: 0.845 p-trend: 0.008 p-trend: <0.001
Monoethyl phthalate (mEP) 4,136 4,136 4,136
continuous 0.08 (0.09) 0.369 0.04 (0.11) 0.693  - <0.001 (<0.001) 0.922
Q1: <50.34 (ref) _ (ref) _ (ref) _
Q2: 50.34-119.09 309.33 (322.12) 0.337 400.16 (399.27) 0.316 0.30 (0.26) 0.249
Q3: 119.10-317.25 -11.40 (333.04) 0.973 442.95 (421.81) 0.283 0.55 (0.26) 0.038
Q4: >317.25 784.81 (348.85) 0.025 1,147 (33) 0.008 0.77 (0.28) 0.005
p-trend: 0.069 p-trend: 0.011 p-trend: 0.004
Monobutyl phthalate (mBP) 4,140 4,140 4,140
continuous -0.04 (0.51) 0.940 0.21 (0.64) 0.746 0.002 (0.004) 0.546
Q1: <10.63 (ref) _ (ref) _ (ref) _
Q2: 10.63-17.85 -176.60 (325.67) 0.588 -0.98 (404.14) 0.998 0.06 (0.26) 0.821
Q3:17.86-30.46 -699.37 (350.56) 0.046 -42.08 (435.03) 0.923 0.30 (0.28) 0.276
Q4: >30.46 -1,177.64 (385.29) 0.002 -650.84 (478.14) 0.174 -0.19 (0.31) 0.540
p-trend: 0.001 p-trend: 0.189 p-trend: 0.737
Monoethylhexyl phthalate (mEHP) 4,140 4,140 4,140
continuous 1.10 (2.58) 0.669 -1.18 (3.20) 0.713 -0.009 (0.002) 0.672
Q1: <1.29 (ref) _ (ref) _ (ref) _
Q2: 1.29-2.67 -174.19 (324.13) 0.591 -223.30 (401.75) 0.578 -0.20 (0.26) 0.430
Q3: 2.68-5.61 -16.64 (322.59) 0.959 -376.73 (399.84) 0.346 -0.24 (0.26) 0.349
Q4: >5.61 57.27 (336.81) 0.865 -622.23 (417.46) 0.136 -0.52 (0.27) 0.054
p-trend: 0.793 p-trend: 0.131 p-trend: 0.064
Monobenzyl phthalate (mBzP) 4,140 4,140 4,140
continuous 0.05 (0.43) 0.909 0.47 (0.54) 0.380 0.004 (0.003) 0.239
Q1: <4.35 (ref) _ (ref) _ (ref) _
Q2: 4.35-7.74 354.67 (324.44) 0.274 579.36 (402.46) 0.150 0.32 (0.26) 0.214
Q3: 7.75-14.01 -356.46 (350.08) 0.351 407.12 (434.27) 0.349 0.43 (0.28) 0.119
Q4: <14.01 -613.23 (388.65) 0.115 848.62 (482.12) 0.078 0.86 (0.31) 0.005
p-trend: 0.037 p-trend: 0.133 p-trend: 0.006
*adjusted for urinary creatinine, age, gender, and race
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Table 13: Number and Percent in Final Sample: NHANES 1999-2006 
 
 
for BPA analysis
(NHANES 03-06)
for phthalate analysis
(NHANES 99-06)
Original Study Sample 2,634 5,688
excluded:
Missing information on 
urinary Phthalate 
metabolites
197 (3.46%)
Missing information on 
urinary BPA
84 (3.19%)
Highly variable 
DXA measures
32 (1.21%)  103 (1.81%)
Final sample size 2,534 (96.20%) 5,436 (95.57%)
DXA measures imputed:
Fat Mass 713 (28.14%) 1,296 (22.78%)
Lean Mass 713 (28.14%) 1,296 (22.78%)
Percent Body Fat 716 (28.26%) 1,296 (22.78%)
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